Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

2 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Assessment of Suspected Pulmonary Embolism

- 06/11/18 - 1 modulo, 9 itemgroups, 32 elementi, 1 linguaggio
Itemgroups: Pulmonary Embolism, Suspicion, Pulmonary Embolism; Lung Scan, Ultrasonography, Venography, Angiogram, Tomography, Spiral Computed, Other Tests, Therapeutic Procedure, Pulmonary Embolism, Seriousness
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Eligibility NCT00439725 Deep Vein Thrombosis - Eligibility

- 09/12/13 - 1 modulo, 3 itemgroups, 17 elementi, 2 lingue
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT or PE who completed 6 or 12 months of treatment with rivaroxaban or VKA are eligible for this trial (Einstein-Extension study).

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial